Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 in moderate to severe atopic dermatitis
NCT04975438Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of aletekitug in atopic dermatitis (AD) (4 arms), sponsored by GSK. Primary endpoint: Percent Change From Baseline in Eczema Area and Severity Index Score at 12 weeks. Started Nov 2021; status: completed.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04975438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975438.